Data / Form D filings / Embold Therapeutics, Inc.
Embold Therapeutics, Inc.: Form D filings
Embold Therapeutics, Inc., a biotechnology company in Redwood City, CA, filed 3 Form D notices with the SEC in 2026. The latest, on July 24, 2026, reports $2.5 million sold of a $5 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2682 EATON AVE, Redwood City, CA, 94062
- Phone
- (650) 200-7297
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2109643
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | Amendment | $4,975,000 | $2,470,587 | $2,504,413 | 7 | Jan 21, 2026 | sec.gov |
| Feb 9, 2026 | New notice | $3,000,000 | $130,000 | $2,870,000 | 2 | Jan 21, 2026 | sec.gov |
| Feb 9, 2026 | New notice | $500,000 | $500,000 | 1 | Jan 21, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Gjalt W. Huisman | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jul 20, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Embold Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.